Sunitinib monotherapy (GIST 2L; imatinib-resistant/intolerant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-SUNITINIB`

ID	`REG-SUNITINIB-GIST-2L`
Type	Regimen
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-GIST-2025`

Notes

Phase III trial (Demetri 2006 Lancet): sunitinib vs placebo in imatinib- resistant/intolerant GIST — mPFS 27.3 vs 6.4 weeks (HR 0.33, p<0.0001). Trial stopped early. FDA approved 2006. KIT exon 9 or wild-type GIST may derive greater benefit than exon 11. Continuous 37.5 mg dosing is an alternative to the 4/2 schedule (per some studies, similar efficacy, improved tolerability). Regorafenib is standard 3L after sunitinib failure.

Used By

Indication

IND-GIST-2L-SUNITINIB - IND-GIST-2L-SUNITINIB

Regimen

REG-SUNITINIB-PHEO - Sunitinib monotherapy (metastatic non-MIBG-avid pheochromocytoma/paraganglioma; FIRSTMAPP...